• Home
  • NEW DAY MEDICINE
  • 5 (67) 2024
  • 147 -5 (67) 2024 - Sabirova S.A., Khakimov G.А. - РELVIC EXENTERATION IN PATIENTS WITH CERVICAL CANCER, CLINICAL EXPERIENCE

147 -5 (67) 2024 - Sabirova S.A., Khakimov G.А. - РELVIC EXENTERATION IN PATIENTS WITH CERVICAL CANCER, CLINICAL EXPERIENCE

РELVIC EXENTERATION IN PATIENTS WITH CERVICAL CANCER, CLINICAL EXPERIENCE

Sabirova S.A. - Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Khakimov G.А. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Khakimova G.G. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Tashmetov M.N. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Jumaniyozov H.I. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Salohiddinov H.A. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Talipov O.A, - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Resume

Despite the progress in pelvic exenteration (PE) technique in international oncological practice, it is still debatable for cancer surgeons. The main reasons for its unpopularity are technical complexity, high rate of intra- and postoperative complications (60%), high postoperative mortality (30%), and challenging postoperative rehabilitation of patients. Aim. To evaluate long-term outcomes after pelvic exenteration in patients with locally advanced recurrent cervical cancer. Materials and methods. From September 2021 to December 2022, 23 PE were performed, including 12 total and 11 anterior. The mean age was 52.2±10.0 years (range 39-83 years). All patients were diagnosed with locally advanced recurrent cervical cancer: 7 (30%) with stage II, 8 (35%) with stage III, and 8 (35%) with stage IV according to the TNM classification. Histologically, cervical cancer was represented by moderately differentiated squamous cell carcinoma. PE was preceded by the following treatments: neoadjuvant chemotherapy in 17 (74%) patients, surgical treatment in 4 (17%) patients and chemoradiotherapy in 2 (9%) patients. More than half (56%) of patients achieved grade 2 therapeutic pathomorphism. The advanced disease involved the following adjacent organs: bladder - 16 (70%), intestines - 13 (56%), endometrium - 7 (30%), myometrium and parametrium - 4 (17%), fallopian tubes, vagina, and ovary – 2 (9%). Results. The average follow-up time for patients was 9.4±8.8 months. Median time to progression – 8.7 months [5.9; 10.8]. During the observation period, 78.3% (18/23) of patients died. Progression was recorded in 39.1% (9/23) of patients. The 1-year overall survival of patients was 38.7% (median 8.9 months). The 1-year tumor-specific survival rate was 60.6% (median 14.1 months). The 1- and 3-year progression-free survival (PFS) rates were 63.0% and 49.0% (median, 13.4 months), respectively. Conclusion. During the observation period, death occurred in 54.6% (12/23) of cases in the anterior PE group, and in 25% (6/23) in the total group. The median overall survival with anterior PE is 2 times higher compared to total PE (9.6 months versus 4.1 months). Median PFS was 13.4 months. For patients after anterior and total pelvic exenteration, 1-year PFS was 51.9±17.6 and 72.9±13.5; 3-year – 25.9±15.7 and 72.9±13.5 (p=0.178), respectively. Thus, PE is justified and significantly expands the possibilities of surgical treatment.

Keywords: cervical cancer, pelvic exenteration, overall survival, progression-free survival

First page

831

Last page

840

For citation:Sabirova S.A., Khakimov G.А., Khakimova G.G., Tashmetov M.N., Jumaniyozov H.I., Salohiddinov H.A., Talipov O.A - РELVIC EXENTERATION IN PATIENTS WITH CERVICAL CANCER, CLINICAL EXPERIENCE//New Day in Medicine 5(67)2024 831-840 https://newdayworldmedicine.com/en/article/3758

List of References

  1. New global cancer data. Available at: www.globocan.com. Accessed: 15.12.2022
  2. Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. M., 2022 [Sostoianiie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 godu. Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow, 2022 (in Russian)].
  3. Петровский Б.В. Большая медицинская энциклопедия. М., 1986. Т. 27; c. 562-3 [Petrovskii BV. Bol'shaya meditsinskaya entsiklopediya. Moscow, 1986. T. 27; p. 562-3 (in Russian)].
  4. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. //Cancer. 1948;1:177-83.
  5. Brunschwig, A. Pelvic exenteration combined with resection of segments of bony pelvis. //Surgery. 1969; 65(3):417-420.
  6. Hugh RK. Treatment and results of recurrent cancer of corpus uteri in patients reseiving anterior and posterior total pelvic exenteration 1947-1963. //Cancer. 1968;22(5):949-55.
  7. Лихтер М.С., Шелыгин Ю.А., Ачкасов С.И. Мультидисциплинарный подход к лечению больных колоректальным раком с вовлечением органов мочевыделительной системы. //Хирургия. Журнал им. Н.И. Пирогова. 2012;12:34-9 [Likhter MS, Shelygin YuA, Achkasov SI. Multidisciplinary approach to the treatment of colorectal cancer, complicated by urinary tract invasion. //Pirogov Russian Journal of Surgery. 2012;12:34-9 (in Russian)].
  8. Одарюк Т.С. Эвисцерация таза при местнораспространенном раке прямой кишки и с прорастанием в мочевой пузырь. //Хирургия. 1999;7:58-63 [Odaryuk TS. Evistseratsiia taza pri mestnorasprostranennom rake priamoi kishki i s prorastaniiem v mochevoi puzyr'. //Khirurgiia. 1999;7:58-63 (in Russian)].
  9. Симонов Н.Н., Гуляев А.В., Максимов С.Я., и др. Эффективность комбинированных резекций и экзентераций органов малого таза как этапа комплексного лечения распространенных злокачественных опухолей прямой кишки и женских гениталий. //Вопросы онкологии. 2000;46(2):224-8 [Simonov NN, Guliaiev AV, Maksimov SIA, et al. Effektivnost' kombinirovannykh rezektsii i ekzenteratsii organov malogo taza kak etapa kompleksnogo lecheniia rasprostranennykh zlokachestvennykh opukholei pryamoi kishki i zhenskikh genitalii. //Voprosy onkologii. 2000;46(2):224-8 (in Russian)].
  10. Тимофеев Ю.М.. Тотальные эвисцерации малого таза при местно-распространенном раке прямой кишки. //Российский онкологический журнал. 2004(5):25-7 [Timofeiev IuM. Total'nyie evistseratsii malogo taza pri mestno-rasprostranennom rake pryamoi kishki. Rossiiskiii onkologicheskii zhurnal. 2004(5):25-7 (in Russian)].
  11. Ильин К.А., Замятин А.В. Роль эвисцерации в лечении постлучевых рецидивов рака шейки матки на современном этапе. //Онкогинекология. 2013(1):43-53 [Iliin KA, Zamiatin AV. The role of pelvic evisceration in the treatment of post-radiation cervical cancer recurrences at the present stage. Onkoginekologiia. 2013(1):43-53 (in Russian)].
  12. Майстренко Н.А., Хватов А.А., Учваткин Г.В., Сазонов А.А. Экзентерация малого таза в лечении местно-распространенных опухолей. //Вестник хирургии. 2014:37-42 [Maistrenko NA, Khvatov AA, Uchvatkin GV, Sazonov AA. Exenteration of the small pelvis in treatment of local tumors. Bulletin of Surgery. 2014;173(6):37-42 (in Russian)].
  13. Grimes WR, Stratton M. Pelvic Exenteration. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK563269/ Accessed: 15.12.2022
  14. Brunschwig A. What are the indications and results of pelvic exenteration?. //JAMA. 1965;194:274-81.
  15. Fleisch MC, Pantke P, Beckmann MW, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. //J Surg Oncol. 2007;95(6):476-84. DOI:10.1002/jso.20686
  16. Lago V, Poveda I, Padilla-Iserte P, et al. Pelvic exenteration in gynecologic cancer: complications and oncological outcome. //Gynecol Surg. 2019;16(1). DOI:10.1186/s10397-019-1055-y
  17. Алиева Г.А. Результаты экзентераций органов малого таза у больных раком шейки матки. //Медицинские новости. 2014;10:66-9 [Aliyeva GA. Result exenteration pelvic organs in patients of servix cance. Meditsinskie novosti. 2014;10:66-9 (in Russian)].
  18. Matylevich OP, Schmeler KM, Polyakov SL, et al. Pelvic Exenteration in Patients with Persistent and Recurrent Cervical Cancer: A Case Series from Belarus. //IJS Oncology. 2021;6(1):1-9. DOI:10.29337/ijsonco.24
  19. Brown KGM, Solomon MJ, Koh CE. Pelvic Exenteration Surgery: The Evolution of Radical Surgical Techniques for Advanced and Recurrent Pelvic Malignancy. /Dis Colon Rectum. 2017;60(7):745-54.
  20. Хирш Х.А. Оперативная гинекология. /М.: ГЭОТАР Медицина, 1999; c. 656 [Khirsh KhA. Operativnaia ginekologiia. Moscow: GEOTAR Meditsina, 1999; p. 656 (in Russian)].

    file

    download